Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas，A Randomized，Double-blind, Placebo-controlled Phase II Trial

NCT04244708 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT04244708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04244708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas，A Randomized，Double-blind, Placebo-controlled Phase II Trial
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
February 10, 2020
Completion date
December 1, 2023
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pituitary adenomas